New drug vs chemotherapy for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your tumor must be esophageal squamous cell carcinoma that cannot be removed by surgery or has spread to other parts of the body.
- You should be able to take care of yourself (ECOG score 0 or 1).
- Your prior cancer treatments must have stopped working or caused side effects that have mostly gone away.
- You cannot have had a previous cancer (other than esophageal) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
This trial compares two treatment approaches for advanced esophageal squamous cell carcinoma (a type of cancer that starts in the lining of the food tube). One group receives chemotherapy combined with an immunotherapy drug before radiation; the other receives chemotherapy and radiation at the same time. The goal is to see which approach works better.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.